Hypertension in HIV-1-infected patients and its impact on renal and cardiovascular integrity

Jung, Ok‐Sang; Bickel, Markus; Ditting, Tilmann; Rickerts, Volker; Welk, Thomas; Helm, E. B.; Staszewski, Schlomo; Geiger, Helmut

doi:10.1093/ndt/gfh393

Cited by 63 publications

(53 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Such conditions affected 13-48% of our subjects, rates similar to those published from other studies of HIV-infected patients. 3,14,15 Our work also demonstrates that many relationships between traditional risk factors and chronic diseases in the general population (e.g., obesity and hypertension) persist for HIV-infected patients. Furthermore, although much has been made of the contribution of antiretroviral therapy toward development of these conditions, our study indicates that the risk conferred by traditional factors is often comparable toand occasionally greater than-that due to antiretroviral therapy.…”

Section: Discussionmentioning

confidence: 53%

Comorbidity-Related Treatment Outcomes among HIV-Infected Adults in the Bronx, NY

et al. 2011

View full text Add to dashboard Cite

Aging, HIV infection, and antiretroviral therapy have been associated with increasing rates of chronic comorbidities in patients with HIV. Urban minority populations in particular are affected by both the HIV/AIDS and chronic disease epidemics. Our objectives were to estimate the prevalence of and risk factors for hypertension, dyslipidemia, and diabetes among HIV-infected adults in the Bronx and describe comorbidity-related treatment outcomes. This was a cross-sectional study of 854 HIV-positive adults receiving care at 11 clinics which provide HIV primary care services; clinics were affiliated with a large urban academic medical center. Data on blood pressure (BP), cholesterol, and glycemic control were collected through standardized chart review of outpatient medical records. We found prevalence rates of 26%, 48%, and 13% for hypertension, dyslipidemia, and diabetes, respectively. Older age, obesity, family history, and current protease inhibitor use were consistently associated with comorbidity. Diabetes treatment goals were achieved less often than BP and lipid goals, and concurrent diabetes was a significant predictor for BP and lipid control. In conclusion, major cardiovascular-related comorbidities are prevalent among HIVpositive adults in the Bronx, especially older and obese individuals. Differences exist in comorbidity-related treatment outcomes, especially for patients with concurrent diabetes. Because cardiovascular risk is modifiable, effective treatment of related comorbidities may improve morbidity and mortality in HIV-infected patients.

show abstract

Section: Discussionmentioning

confidence: 53%

Comorbidity-Related Treatment Outcomes among HIV-Infected Adults in the Bronx, NY

et al. 2011

View full text Add to dashboard Cite

show abstract

“…Highly active antiretroviral therapy has been linked to hypertension in a few but not all studies. In a retrospective analysis by Cattelan et al (39), a significant increase in both systolic and diastolic BP was noted in HIV-infected patients who were on long-term therapy with indinavir compared with baseline BP before protease inhibitor therapy; however, Jung et al (40) observed no significant difference between hypertensive and normotensive patients when comparing current as well as total duration of specific antiretroviral drugs or combination regimen. Because we excluded all patients with hypertension in the analysis, it is unlikely that the renal vascular damage observed in our study is linked to highly active antiretroviral therapy.…”

Section: Discussionmentioning

confidence: 99%

Cocaine Use and Hypertensive Renal Changes in HIV-Infected Individuals

Fine

Garg

Haas

et al. 2007

Clinical Journal of the American Society of Nephrology

View full text Add to dashboard Cite

Background and objectives: Cocaine causes kidney damage, but data linking cocaine use to chronic kidney disease in HIV patients is not described. This study was conducted to evaluate the possible association of cocaine use and histopathologic findings on biopsy in this population.Design, setting, participants, & measurements: Kidney biopsies that were performed in HIV-infected patients during the course of 11 yr were reviewed. Demographic and clinical data were collected. Hypertensive changes were defined on the basis of the Banff 97 classification. Criteria of both arterial intimal fibrosis and thickening and hyaline arteriolosclerosis were used and graded as absent (0), mild (1), moderate (2), and severe (3). Hypertensive renal changes were considered present when the combined pathology score was >2. To minimize confounding, those with hypertension or diabetes were excluded.Results

show abstract

“…Thus the risk of cardiovascular disease was significantly higher in patients with MS. Hadigan et al (2001) Before the advent of HAART, hypertension was often reported in patients infected with HIV (Iwuala, 2008). Recent studies highlight hypertension increasingly observed in patients infected with HIV on antiretroviral therapy (Gazzaruso et al, 2003;Jung et al, 2004). Blood pressure up than 130/85 mmHg was found in 13.9% of our study population receiving ARV treatment.…”

Section: Resultsmentioning

confidence: 61%

“…Muhammad et al (2013) reported a prevalence of 17% of hypertension cases in HIV patients mainly on NNRTI-based HAART during 6-84 months. In Western countries, many studies showed hypertension proportion among HIV patients on HAART ranging from 13% to 34% (Gazzaruso et al, 2003;Jung et al, 2004;Bergersen et al, 2003;Medina-Torne et al, 2012;Savès et al, 2003).…”

Section: Resultsmentioning

confidence: 99%

Biological and clinical abnormalities leading to cardiovascular disease during antiretroviral treatment in a university hospital in Abidjan

Kouakou-Siransy¹,

Horo²,

Effo³

et al. 2015

Int. J. Bio. Chem. Sci

View full text Add to dashboard Cite

Antiretroviral drugs are involved in the occurrence of adverse effects. In Côte d'Ivoire, HIV1 treatment protocols are non-nucleoside reverse transcriptase inhibitors based. No study has been undertaken in the country about cardiovascular risk. Thus, the objective of our study was to assess the prevalence of biological abnormalities and clinical markers of cardiovascular risk during antiretroviral therapy. We conducted a prospective cross-sectional study with 238 patients who were on antiretroviral treatment including nonnucleoside reverse transcriptase inhibitors for at least 6 months in the Pneumophtisiology department of the university hospital of Cocody (Abidjan). Metabolic syndrome was determined according to NCEP-ATP III criteria. Biological parameters investigated were: triglyceride, HDL cholesterol and LDL, glucose and clinical parameters: blood pressure and waist circumference. Eleven patients (4.62%) have a metabolic syndrome, 17.6% had hypertriglyceridemia. An increase in LDL cholesterol and lower HDL-cholesterol were found in both cases in 13.9% of patients and an atherogenic index greater than 4.5 in 5% of patients. Hyperglycemia occurred during antiretroviral therapy in 28% of the study population. Patients who developed hypertension and increased waist circumference during antiretroviral therapy were 9.75% and 15.5% respectively. Our results testify to the potential existence of a cardiovascular risk during the non-nucleoside inhibitor used.

show abstract

Hypertension in HIV-1-infected patients and its impact on renal and cardiovascular integrity

Cited by 63 publications

References 17 publications

Comorbidity-Related Treatment Outcomes among HIV-Infected Adults in the Bronx, NY

Comorbidity-Related Treatment Outcomes among HIV-Infected Adults in the Bronx, NY

Cocaine Use and Hypertensive Renal Changes in HIV-Infected Individuals

Biological and clinical abnormalities leading to cardiovascular disease during antiretroviral treatment in a university hospital in Abidjan

Contact Info

Product

Resources

About